2012 competition in the pharmaceutical industry marketing strategies（2012年医药行业营销策略的竞争）.docVIP

下载本文档

1
0
约1.36万字
约 12页
2017-09-05 发布于浙江
举报
版权申诉

2012 competition in the pharmaceutical industry marketing strategies（2012年医药行业营销策略的竞争）.doc

1、本文档共12页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

2012 competition in the pharmaceutical industry marketing strategies（2012年医药行业营销策略的竞争）

2012 competition in the pharmaceutical industry marketing strategies This is an era of changing the pharmaceutical industry: the Ministry of repeated major second Five-Year plan, the new pharmaceutical industry policy, Anhui mode, Shanghai mode, Beijing model of primary health care reform breakthrough, based medicine double envelope, big double standard envelope, ... but also a time of opportunity: the size of the Chinese pharmaceutical market in 2011 reached 907.8 billion yuan, up 20.1% compared to 2010, pharmaceutical industrial output value of 1.5223 trillion yuan, up 23.3% compared to 2010, while the increase in government large investment, primary market continued expansion, external appearance of the pharmaceutical industry slightly decadent, filled with numerous variables within the same time, China’s pharmaceutical enterprises for several years, has experienced many ups and downs, market competition and corporate transformation everywhere, changing reality, constantly exposed to the problem, although you can get a lot of market development funds, although within the enterprise can be achieved through the IPO leadership dream of becoming rich, but everything will be attributed to silence, because of a temporary aura can not cover the basic needs of enterprise development - core competencies, we can use the power of capital to obtain scale advantages, but the company eventually developed and long-term planning based on business operations or from the most basic elements - business marketing. This is an era of transformation of China’s pharmaceutical industry, which is a Chinese pharmaceutical companies must be a choice of times and return to our main business, to see fundamental to our survival, in order to form the next journey of our own competitive advantage, the formation of characteristics of our own marketing to the future development lopsided. Then in 2012, how pharmaceutical companies overall marketing decision? Professional to do the PKU medical